Table 2. Quantitative sensory tests in intermediate and extensive metabolizers.

	Time	2D6 subtype	Marginal mean ratio (95% CI)	p value	p value for interaction
ESPT	60	intermediate metabolizer	1.20 (1.10 to 1.31)	0.000	0.007
		extensive metabolizer	1.03 (0.96 to 1.11)	0.403
	120	intermediate metabolizer	1.15 (1.04 to 1.26)	0.006
		extensive metabolizer	0.99 (0.90 to 1.07)	0.736
ERPT	60	intermediate metabolizer	1.08 (0.98 to 1.18)	0.111	0.079
		extensive metabolizer	0.97 (0.89 to 1.05)	0.451
	120	intermediate metabolizer	1.05 (0.96 to 1.16)	0.284
		extensive metabolizer	0.95 (0.87 to 1.03)	0.223
PPDT	60	intermediate metabolizer	1.10 (1.01 to 1.21)	0.034	0.054
		extensive metabolizer	0.99 (0.91 to 1.07)	0.722
	120	intermediate metabolizer	1.07 (0.97 to 1.17)	0.169
		extensive metabolizer	0.96 (0.88 to 1.04)	0.278
PPTT	60	intermediate metabolizer	1.01 (0.94 to 1.08)	0.767	0.475
		extensive metabolizer	0.98 (0.92 to 1.04)	0.506
	120	intermediate metabolizer	1.07 (1.00 to 1.15)	0.047
		extensive metabolizer	1.04 (0.98 to 1.11)	0.210
Iwsec	60	intermediate metabolizer	1.20 (1.02 to 1.42)	0.032	0.231
		extensive metabolizer	1.05 (0.91 to 1.21)	0.483
	120	intermediate metabolizer	1.17 (0.98 to 1.40)	0.080
		extensive metabolizer	1.03 (0.88 to 1.20)	0.722

Effect of imipramine vs. placebo on pain detection threshold with a single (ESPT) or repeated electrical stimulus (ERPT), and on pressure pain detection (PPDT) and tolerance thresholds (PPTT), and the time until cold pain reaches 7 on NRS (Iwsec) for different CYP 2D6 genotypes (intermediate vs. extensive metabolizers). The effect is estimated on the log scale and presented as a mean ratio. A significant interaction would indicate that the effect differs between genotypes.